Antitrust Antitrust

US FTC’s Khan disappointed after commission rejects move to investigate pharmacy benefit managers’ drug pricing, contracts

By Khushita Vasant
  • 17 Feb 2022 17:59
  • 17 Feb 2022 18:53
US Federal Trade Commission chair Lina Khan today said she was “really disappointed” after a split agency vote led to the failure of a motion seeking to investigate pharmacy benefit managers’ drug pricing and contracting practices and their impact on competition and consumers' healthcare costs.
During the agency's monthly Open

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Khushita Vasant

Chief Antitrust Correspondent, US

Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.

Discover MLex

Stay on top of global regulatory developments

Latest News